Phama: Execute expansion strategy and contribute to profit in Overseas Business

Meiji Holdings Co., Ltd. Financial Results- For the First Half of FYE March 2017 -

	TOP

	Financial Results - For the First Half of FYE March 2017 -

	1. Overview for the First Half

	2. Outlook for the Second Half and Full-year

	3. Progress in STEP UP 17 strategy: Our strategic efforts to address issues Food: Increase in Sales and Market Share of Core Products Enhancing Added Values (1) Food: Increase in Sales and Market Share of Core Products Enhancing Added Values (2) Food: Structural Reform in Processed Food business: Selection and Concentration Resulted in Improved Profitability Food: Establish Effective Logistics System to Decrease Logistics Costs Food: Increase Profitability by Expanding Sales in Overseas Business Phama: Establish Market Presence for Newly Launched Products and Boost Sales of Existing Products in Domestic Business Phama: Execute expansion strategy and contribute to profit in Overseas Business Phama: Focus on Our Expertise to Develop New Drugs

	100 YEARS YOUNG

	Appendix

Phama: Execute expansion strategy and contribute to profit in Overseas Business

Prev. Page

Next Page

Download the PDF

Overseas business
Our overseas business must contribute to both sales increase and cost competitiveness.

Favorable on local currency basis. In particular, our Indonesian subsidiary is growing.
Achieving inter-Group synergy.

- Medreich Far East Ltd. (Hong Kong) released Meiact, our mainstay antibiotics.

- Overseas Group companies began marketing Medreich products.

Intense price competition in the Japanese generic market.
Manufacture generic drugs for Japanese market in Medreich

- Completed construction of a manufacturing site for the Japanese market.

- The first shipment is scheduled for FYE March 2018.